FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387062172> ?p ?o ?g. }

• W4387062172 endingPage "728" @default.
• W4387062172 startingPage "727" @default.
• W4387062172 abstract "The quantification of urine epidermal growth factor (uEGF) as a novel biomarker of renal health in various renal diseases is gradually increasing. The activation uEGF assists in promoting multiple intracellular pathways, stimulating cell growth, survival, and replication in the kidneys. uEGF production is activated by multiple stimulating agonists that are activated by binding to the uEGF receptor. The usefulness of uEGF agonists may assist in screening and diagnosing individuals at risk for developing renal decline and chronic kidney disease (CKD). PURPOSE: To determine the association and predictability of uEGF agonists (serum insulin-like growth factor 1 (IGF-1), angiotensin II receptor type 1 (AGTR-1), and transforming growth factor-beta 1 (TGF-β1)) to CKD stage and renal health. METHODS: A total of 20 participants (n = 14 women; n = 6 men; age 62.0 + 9.9 yr.; eGFR 51.5 + 6.5 mL/min/1.73m2; BF 37.3 + 8.5%) underwent a standard screening session which included blood and urine samples. Agonists of uEGF included serum IGF-1 (ng/mL), AGTR-1 (ng/mL), and TGF-β1 (pg/mL), along with uEGF (ng/mL) concentrations. Serum creatinine and albumin were obtained to determine CKD stage via estimated glomerular filtration rate (eGFR) and overall renal filtration. The data were analyzed using Pearson Correlation to compare uEGF agonists concentrations to CKD stage and renal health. In addition, a multiple linear regression analysis was performed to examine the relationship between uEGF agonist’s ability to predict CKD stage and renal health. All analyses were performed using SPSS (v. 28.0.1.1). RESULTS: Serum TGF-β1 was negatively correlated to eGFR (r = -0.547, p = 0.019). Additionally, albumin was negatively correlated to uEGF (r = -0.587, p = 0.007). There were no other significant correlations between uEGF and CKD stage and renal health. TGF-β1 was the only agonist able to significantly predict CKD stage (eGFR) (R2 = 0.299, p = 0.019). CONCLUSIONS: Agonist of uEGF TGF-β1 was able to independently predict eGFR and was also negatively correlated to eGFR, indicating that as TGF-β1 increases eGFR decreases. Thus, a potentially adverse effect on renal health is activated. Therefore, further research is needed to better elucidate the role of uEGF agonists and their influence in assessing individuals at risk for developing CKD." @default.
• W4387062172 created "2023-09-27" @default.
• W4387062172 creator A5003679897 @default.
• W4387062172 creator A5028701540 @default.
• W4387062172 creator A5032354133 @default.
• W4387062172 creator A5041858322 @default.
• W4387062172 creator A5065421507 @default.
• W4387062172 creator A5080607725 @default.
• W4387062172 creator A5084889701 @default.
• W4387062172 date "2023-09-01" @default.
• W4387062172 modified "2023-09-27" @default.
• W4387062172 title "The Utilization Of Urine Epidermal Growth Factor Agonists To Predict Chronic Kidney Disease Stage And Renal Health" @default.
• W4387062172 doi "https://doi.org/10.1249/01.mss.0000986668.48147.17" @default.
• W4387062172 hasPublicationYear "2023" @default.
• W4387062172 type Work @default.
• W4387062172 citedByCount "0" @default.
• W4387062172 crossrefType "journal-article" @default.
• W4387062172 hasAuthorship W4387062172A5003679897 @default.
• W4387062172 hasAuthorship W4387062172A5028701540 @default.
• W4387062172 hasAuthorship W4387062172A5032354133 @default.
• W4387062172 hasAuthorship W4387062172A5041858322 @default.
• W4387062172 hasAuthorship W4387062172A5065421507 @default.
• W4387062172 hasAuthorship W4387062172A5080607725 @default.
• W4387062172 hasAuthorship W4387062172A5084889701 @default.
• W4387062172 hasBestOaLocation W43870621721 @default.
• W4387062172 hasConcept C126322002 @default.
• W4387062172 hasConcept C126894567 @default.
• W4387062172 hasConcept C134018914 @default.
• W4387062172 hasConcept C159641895 @default.
• W4387062172 hasConcept C2778653478 @default.
• W4387062172 hasConcept C2780026642 @default.
• W4387062172 hasConcept C2780091579 @default.
• W4387062172 hasConcept C2780306776 @default.
• W4387062172 hasConcept C71924100 @default.
• W4387062172 hasConceptScore W4387062172C126322002 @default.
• W4387062172 hasConceptScore W4387062172C126894567 @default.
• W4387062172 hasConceptScore W4387062172C134018914 @default.
• W4387062172 hasConceptScore W4387062172C159641895 @default.
• W4387062172 hasConceptScore W4387062172C2778653478 @default.
• W4387062172 hasConceptScore W4387062172C2780026642 @default.
• W4387062172 hasConceptScore W4387062172C2780091579 @default.
• W4387062172 hasConceptScore W4387062172C2780306776 @default.
• W4387062172 hasConceptScore W4387062172C71924100 @default.
• W4387062172 hasIssue "9S" @default.
• W4387062172 hasLocation W43870621721 @default.
• W4387062172 hasOpenAccess W4387062172 @default.
• W4387062172 hasPrimaryLocation W43870621721 @default.
• W4387062172 hasRelatedWork W2042033030 @default.
• W4387062172 hasRelatedWork W2046899919 @default.
• W4387062172 hasRelatedWork W2124543160 @default.
• W4387062172 hasRelatedWork W2127085070 @default.
• W4387062172 hasRelatedWork W2140445493 @default.
• W4387062172 hasRelatedWork W3011378569 @default.
• W4387062172 hasRelatedWork W3117361317 @default.
• W4387062172 hasRelatedWork W3133946270 @default.
• W4387062172 hasRelatedWork W393698729 @default.
• W4387062172 hasRelatedWork W4280508227 @default.
• W4387062172 hasVolume "55" @default.
• W4387062172 isParatext "false" @default.
• W4387062172 isRetracted "false" @default.
• W4387062172 workType "article" @default.